Insider Transactions in Q2 2023 at Amneal Pharmaceuticals, Inc. (AMRX)
Insider Transaction List (Q2 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2023
|
Andrew S Boyer Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
11,571
-4.05%
|
$34,713
$3.1 P/Share
|
|
Jun 30
2023
|
Andrew S Boyer Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
23,095
+7.48%
|
-
|
|
May 10
2023
|
Ted C Nark Director |
BUY
Exercise of conversion of derivative security
|
Direct |
80,128
+26.32%
|
-
|
|
May 10
2023
|
Jeffrey P. George Director |
BUY
Exercise of conversion of derivative security
|
Direct |
80,128
+29.33%
|
-
|
|
May 10
2023
|
Gautam Patel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
80,128
+17.63%
|
-
|
|
May 10
2023
|
J Kevin Buchi Director |
BUY
Exercise of conversion of derivative security
|
Direct |
80,128
+30.15%
|
-
|
|
May 10
2023
|
Shlomo Yanai Director |
BUY
Exercise of conversion of derivative security
|
Direct |
80,128
+32.13%
|
-
|
|
May 10
2023
|
John Kiely Director |
BUY
Exercise of conversion of derivative security
|
Direct |
80,128
+30.89%
|
-
|
|
May 10
2023
|
Emily Peterson Alva Director |
BUY
Exercise of conversion of derivative security
|
Direct |
80,128
+31.49%
|
-
|
|
May 10
2023
|
Paul M Meister Director |
BUY
Exercise of conversion of derivative security
|
Direct |
112,179
+15.31%
|
-
|